CPC C07K 16/3092 (2013.01) [A61K 39/39558 (2013.01); A61K 39/39591 (2013.01); A61K 47/60 (2017.08); A61K 51/1045 (2013.01); A61K 51/1093 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); G01N 2333/4728 (2013.01)] | 10 Claims |
1. A method for in vitro immunodetection of TAG-72-expressing cancer cells comprising a step of contacting the cancer cells with an antibody fragment which specifically binds tumor-associated glycoprotein 72 (TAG-72), wherein the antibody fragment comprises an amino acid sequence with 98% or more identity to SEQ ID NO: 13, 33, 35, 37, 39, 41, 43, or 45, wherein said antibody fragment comprises complementarity determining regions (CDRs), wherein said CDRs comprise amino acid residues 53-57, 72-88, 122-126, 166-182, 198-204, and 237-245 of SEQ ID NO: 13; residues 76-80, 95-111, 144-149, 189-205, 221-227, and 260-268 of SEQ ID NO: 33; residues 76-80, 95-111, 144-149, 209-225, 241-247, and 280-288 of SEQ ID NO: 35; residues 76-80, 95-111, 144-149, 204-220, 236-242, and 275-283 of SEQ ID NO: 37; residues 76-80, 95-111, 144-149, 199-215, 231-237, and 270-278 of SEQ ID NO: 39; residues 76-80, 95-111, 144-149, 188-204, 220-226, and 259-267 of SEQ ID NO: 41; residues 76-80, 95-111, 144-149, 188-204, 220-226, and 259-267 of SEQ ID NO: 43; and residues 76-80, 95-111, 144-149, 189-205, 221-227, and 260-268 of SEQ ID NO: 45; or wherein the antibody fragment comprises SEQ ID NOS: 15, 17, 19, 21, 23, 25, 27, 29, or 31.
|